An optical spectroscopic approach for quantifying Hb/Mb ratio noninvasively noninvasively

Introduction Impaired blood flow and mitochondrial defects are involved in a wide variety of metabolic and degenerative diseases. The inability to quantify tissue hemoglobin (Hb) content presents a significant barrier to non-invasive assessment of regional mitochondrial function in blood flow. Technology description Researchers at the University of Washington have developed an approach for the noninvasive determination of local Hb concentration in skeletal muscle. The approach uses the spectral shift between Hb and myoglobin (Mb) in the near-infrared to quantify the ration of Hb/Mb non-invasively. This approach will help assess mitochondrial metabolism and regional blood flow and improve diagnosis and monitoring of interventions for a wide variety of degenerative pathologies. Business opportunity Applications for this new spectroscopic approach include diagnosis of vascular or mitochondrial disorder, exercise science, and athletic training. It is valuable technology in a health and fitness market that is expanding rapidly, especially as the number of Americans 55 or older increases rapidly. Stage of development Initial patient data has been obtained using this approach. Intellectual property position The technology is available for licensing. The UW has a US patent pending for this technology. Related Publication(s)
Marcinek et al. Appl Spectrosc. 2007 Jun: 61(6):665-9 For more information on this technology contact:
Chris Igielski Technology Manager cti2@u.washington.edu 206-685-4681

Type of Offer: Licensing



Next Patent »
« More Life Sciences Patents
« More Medical Patents

Share on        


CrowdSell Your Patent